VivoSeq
Other

Stem Cell

0

Pipeline Programs↗

8

Active Trials↗

3

Companies Involved↗

Stem Cell is an early-stage landscape with 0 programs across 3 companies. The most active players are Celldex Therapeutics, Sanofi, Teva.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Celldex Therapeutics

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalTeva logo

Teva

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

49

clinical trials

Completed24 · 49%
Unknown status9 · 18%
Recruiting6 · 12%
Terminated6 · 12%
No longer available1 · 2%
Active, not recruiting1 · 2%
Other2 · 4%

Clinical Trials

Trial Activity

49 trials

SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT06442761·15 enrolled
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Recruiting·RRuijin Hospital·Phase 2·NCT06589089·18 enrolled
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06193486·30 enrolled
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
Recruiting·—·Phase 2·NCT05052957·16 enrolled
Eltrombopag for Peripheral Blood Stem Cell Harvest
Recruiting·NNational Taiwan University Hospital·Phase 2·NCT05961410·46 enrolled
Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy
Recruiting·DDr.dr.Irma Bernadette, SpKK (K)·N/A·NCT06516419·90 enrolled
Autologous Stem Cell Study for Adult TBI (Phase 2b)
Active, not recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02525432·37 enrolled
BANDICOOT: An Adaptive Platform Trial Designed to Improve the Complications, Cost-effectiveness and Health Outcomes for Children Receiving a Stem Cell Transplant
Not yet recruiting·MMurdoch Childrens Research Institute·Preclinical·NCT07679100·10,000 enrolled
Skin Rejuvenation Using Stem Cell Secretome
Completed·CCOR clinic of Regenerative Medicine·Phase 1·NCT06217627·49 enrolled
Comparison Between Skin Graft Versus Skin Graft and Stem Cell Application
Completed·KKing Edward Medical University·Phase 1·NCT04219657·110 enrolled
A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers
Completed·BBioLineRx, Ltd.·Phase 1·NCT02073019·33 enrolled
Plerixafor for Stem Cell Mobilization in Normal Donors
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01818284·22 enrolled
A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT00005783·50 enrolled
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Completed·—·Phase 2·NCT00368355·46 enrolled
TevaGastrim for Stem Cell Mobilization Sibling Donors
Completed·SSheba Medical Center·Phase 2·NCT01542944·24 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)